AMLX Stock Recent News
AMLX LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences.
The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 105.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome.
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Lindsey Allen - Vice President Investor Relations and Communications Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-CEO Conference Call Participants Michael DiFiore - Evercore ISI Marc Goodman - Leerink Tim Anderson - Bank of America Securities Graig Suvannavejh - Mizuho Joe Beatty – Baird Ananda Ghosh - H.C. Wainwright & Company Dan Akschuti - Pareto Securities Operator Good morning, my name is Liane and I will be your conference operator today.